Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Published Online: 2014-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Andreas Günther•Ashraf Elghandour•Bourras-Rezki Bengoudifa•Claudia Corrado•Darrell White•Daryl Tan•Enrique M Ocio•Florence Binlich•Hans Salwender•Hareth Nahi•Hermann Einsele•Jae Hoon Lee•Jamie D Cavenagh•Javier de la Rubia•Je-Jung Lee•Jesús F San-Miguel•Jian Hou•Joan Bladé•Jonathan L Kaufman•Krzysztof Warzocha•Kwee Yong•Ljupco Veskovski•Lugui Qiu•Meletios Athanasios Dimopoulos•Meral Beksac•Ming-Chung Wang•Monika Sopala•Noppadol Siritanaratkul•Paolo Corradini•Paul G Richardson•Peter Gimsing•Philippe Moreau•Richard LeBlanc•Robert L Schlossman•Sagar Lonial•Sang Kyun Sohn•Stefano Pulini•Sung-Soo Yoon•Suporn Chuncharunee•Tatiana Shelekhova•Thanyaphong Na Nakorn•Tontanai Numbenjapon•Vânia T M Hungria•WenMing Chen•Wieslaw Wiktor Jedrzejczak
